Mantle Cell Lymphoma | Specialty

Dr. Goy on the Potential Utility of Liso-Cel in MCL

April 19th 2021

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Tazemetostat Displays Promising Preclinical Activity in BTK-Resistant MCL Cell Lines

April 16th 2021

Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.

Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

April 14th 2021

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Dr. Jain on Ongoing Research Efforts in MCL

April 12th 2021

Preetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.

Pirtobrutinib Showcases Encouraging Activity in CLL, MCL, and Other B-Cell Malignancies

April 8th 2021

Pirtobrutinib showcased encouraging efficacy with an acceptable safety profile in patients with chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia who previously received a BTK inhibitor.

Dr. Goy on the Clinical Implications of CAR T-Cell Therapy in MCL

April 8th 2021

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Dr. Till on the Utility of Brexucabtagene Autoleucel in MCL

April 6th 2021

Brian Till, MD, discusses the utility of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Martin on the Utility of CAR T-Cell Therapy in High-Risk MCL

April 2nd 2021

Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.

Dr. Martin on Selecting Among FDA-Approved BTK Inhibitors in MCL

March 19th 2021

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Liso-Cel Shows Encouraging Clinical Activity, Safety in Relapsed/Refractory MCL

March 19th 2021

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

x